Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light chain forming amyloid deposits in tissue. The heart and kidney are the major organs affected, but all others, with the exception of the CNS, can be involved. The disease is rapidly...
Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis: Amyloid: Vol 17, No 3-4 Saraiva, M.J., et al.: Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of...
An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Sanchorawala V,Wright D G,Seldin D C,et al. Bone Marrow Transplantation . 2001V. Sanchorawala, D. G. Wright, D. C. Seldin et al., "An overview of the use of...
Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. Methods: We performed a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of eprodisate in patients with ... Dember,Laura,M.,... - 《New England Journal of Medicine》 被引量...
No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy ... MA Gertz,SR Zeldenrust - 《Curr Hematol Malig Rep》 被引量: 171发表: 2009年 Light chain (AL) amyloidosis: update on diagnosis and manage...
Present possibilities of diagnosis and treatment of systemic AL-amyloidosisŠčudla, VPika, T
An up-to-date reference on this fascinating set of complex disorders, this book features the most comprehensive strategies for diagnosing, classifying, imaging, treating, and managing amyloidosis in multiple organ systems. Beneficial to the spectrum of practitioners from residents to sub-specialists, ...
Amyloidosis is a disease in which abnormal proteins form fibrillar tissue deposits that can compromise key viscera and lead to early death. In order to tre
We report results of a phase II trial of combination of melphalan, lenalidomide, and dexamethasone for the treatment of immunoglobulin light chain (AL) amyloidosis. The primary objectives were tolerability and hematologic response rate; secondary objectives were organ responses and survival. Treatment pro...
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressive chemotherapy, and almost all patients eventually...